caa a22 4500 605490376 CHVBK 20210128100504.0 cr unu---uuuuu 210128e20150201xx s 000 0 eng 10.1007/s10147-014-0694-2 doi (NATIONALLICENCE)springer-10.1007/s10147-014-0694-2 Estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer: a retrospective consecutive case series [Elektronische Daten] [Gaetano Aurilio, Rossella Graffeo, Vincenzo Bagnardi, Franco Nolè, Laura Adamoli, Olivia Pagani, Elisa Gallerani, Benvenuto Ferrari, Giancarlo Pruneri, Aron Goldhirsch] Background: Estramustine phosphate sodium (EMP) is an oral agent poorly developed—although active—in patients with metastatic breast cancer (MBC). To resume interest in EMP in MBC, we analyzed a retrospective series of consecutive patients with estrogen receptor-positive disease. Methods: EMP was given orally at a dose of 140mg daily. Treatment discontinuation rates due to progressive disease/toxicity and response rates were assessed. Results: Twenty postmenopausal patients with mainly visceral disease were treated with EMP, in five cases in combination with other anticancer drugs. Median numbers of previous chemotherapies and hormonal treatments were six and four, respectively. From the entire cohort, one complete response and four partial responses were observed. The proportions of patients free of progression at 6 and 12months were 39 and 8%, respectively. Six patients discontinued EMP, three each for toxicity and adverse events. Conclusion: Good disease control was obtained in heavily pretreated MBC patients receiving EMP. Toxicity was manageable and reversible although treatment discontinuation has to be considered. A prospective study should be encouraged to identify the optimal use of the drug. Japan Society of Clinical Oncology, 2014 Estramustine phosphate sodium nationallicence Metastatic nationallicence Breast cancer nationallicence Aurilio Gaetano Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy aut Graffeo Rossella Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy aut Bagnardi Vincenzo Division of Epidemiology and Biostatistics, European Institute of Oncology, Via Ripamonti 435, Milan, Italy aut Nolè Franco Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy aut Adamoli Laura Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy aut Pagani Olivia Department of Medical Oncology, Oncology Institute of Southern Switzerland, Ospedale Italiano, Via Capelli, 6962, Viganello, Lugano, Switzerland aut Gallerani Elisa Multimedica Castellanza, Viale Piemonte 70, 21053, Castellanza, Varese, Italy aut Ferrari Benvenuto Multimedica Castellanza, Viale Piemonte 70, 21053, Castellanza, Varese, Italy aut Pruneri Giancarlo Department of Pathology, European Institute of Oncology, Via Ripamonti 435, Milan, Italy aut Goldhirsch Aron Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy aut International Journal of Clinical Oncology Springer Japan 20/1(2015-02-01), 90-94 1341-9625 20:1<90 2015 20 10147 https://doi.org/10.1007/s10147-014-0694-2 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0694-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Aurilio Gaetano Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy aut NATIONALLICENCE 700 1- Graffeo Rossella Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy aut NATIONALLICENCE 700 1- Bagnardi Vincenzo Division of Epidemiology and Biostatistics, European Institute of Oncology, Via Ripamonti 435, Milan, Italy aut NATIONALLICENCE 700 1- Nolè Franco Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy aut NATIONALLICENCE 700 1- Adamoli Laura Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy aut NATIONALLICENCE 700 1- Pagani Olivia Department of Medical Oncology, Oncology Institute of Southern Switzerland, Ospedale Italiano, Via Capelli, 6962, Viganello, Lugano, Switzerland aut NATIONALLICENCE 700 1- Gallerani Elisa Multimedica Castellanza, Viale Piemonte 70, 21053, Castellanza, Varese, Italy aut NATIONALLICENCE 700 1- Ferrari Benvenuto Multimedica Castellanza, Viale Piemonte 70, 21053, Castellanza, Varese, Italy aut NATIONALLICENCE 700 1- Pruneri Giancarlo Department of Pathology, European Institute of Oncology, Via Ripamonti 435, Milan, Italy aut NATIONALLICENCE 700 1- Goldhirsch Aron Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/1(2015-02-01), 90-94 1341-9625 20:1<90 2015 20 10147